Manufacturer of TACHYRA TABLET 200 mg
Tachyra tablet is
manufactured by Cipla LTD .
Content of Tachyra tablet 200 mg
Tachyra tablet
contains Amiodarone hydrochloride .Amiodarone hydrochloride is a class 3 antiarrhythmic
drug.Arrhythmia is a condition in which the heart beats an irregular or
abnormal rhythm.
Uses of Tachyra tablet 200 mg
- Ventricular arrhythmias
- Pulseless ventricular fibrillations(It is an
irregular rhythm caused by rapid,uncoordinated fluttering contractions of
the heart's lower chambers)
- Ventricular tachycardia(It is a fast heart's beat and a
pulse of more than 100 beats per minute)
- Atrial flutter and fibrillations
- All types of paroxysmal tachycardia(Paroxysmal atrial
tachycardia is a type of arrhythmia or irregular heartbeat)
Contraindications of Tachyra tablet 200 mg
Hypersensitive to
amiodarone or iodine.
Severe sinus node
dysfunction .
2 & 3 degree heart block.
Cardiogenic shock.
Pregnancy.
Precautions of Tachyra tablet 200 mg
Liver-function and
thyroid -functions tests required before treatment and then every 6
months:hypokalemia(measure serum -potassium concentration before treatment
:severe bradycardia and conduction disturbance in excessive dosage :blood
pressure monitored closely .
Adverse effects of Tachyra tablet 200 mg
- Nausea
- Vomiting
- taste disturbance
- Raised serum transaminases (liver enzymes )
- Jaundice
- Bradycardia(abnormally slow heart action)
- Pulmonary toxicity(pneumonitis and fibrosis)
- Tremor
- Sleep disorders
- Hypothyroidism or hyper
- Reversible corneal microdeposits
- Phototoxicity
- Peripheral neuropathy or myopathy (usually reversible
on withdrawal)
- Hypersensitivity reactions
- Chronic liver diseases
- Hemolytic or aplastic anemia
- Optic neuritis
If any of the event occurred
please contact your concerned doctor .
Pregnancy category -D
There is positive
evidence of human fetal risk based on adverse reaction data from
investigational or marketing experience or studies in humans, but potential
benefits may warrant use of the drug in pregnant women despite potential
risks.
0 comments:
Post a Comment